EUVIMEDObjevte EUVIMED
EditorialOpen access · CC BY 4.0

Extended Insights Into Advancing Multi-Omics and Prognostic Methods for Cancer Prognosis Forecasting

Jindong Xie, Junjie Xu, Zhi Tian, Jian Liang, Hailin Tang

Frontiers in Bioscience-Landmark · 2025-08-30 · 30 (8)

DOI: 10.31083/fbl44091 ↗

At a glance

Editorial in Frontiers in Bioscience-Landmark, published online on 2025-08-30. Written by Jindong Xie and 4 co-authors. Institution: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 5100…. Major MEDLINE topics: Adenocarcinoma of Lung, Biomarkers, Tumor, Lung Neoplasms. Cited 7 times so far (Crossref); 17 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Zhang et al.’s recent article utilizes comprehensive single-cell data to identify differences in tumor cell populations, highlighting the CKS1B+ malignant cell subcluster as a potential target for immunotherapy. It develops a prognostic and immunotherapeutic signature (PIS) based on this subcluster, demonstrating good performance in predicting lung adenocarcinoma (LUAD) prognosis. The study also validates the role of PSMB7 in LUAD progression. However, there are areas for improvement. There is a lack of clarity regarding the relationship between the CKS1B+ malignant cell subcluster and the PIS, particularly in terms of why PSMB7 was selected for functional studies. The sequencing data are retrospectively obtained from public databases and lack prospective clinical validation. It is suggested to collect LUAD patient tissues for RT-qPCR and RNA-seq analysis and seek external multi-center validations. Additionally, integrating emerging multi-omics methods is recommended to further validate the findings. Despite these limitations, the study represents progress in understanding LUAD and treatment strategies, and continuous evaluation and refinement of multi-omics and machine learning methods are expected for future research and clinical practice.

Subjects

MeSH terms (MEDLINE)

Adenocarcinoma of LungBiomarkers, TumorLung NeoplasmsHumansGene Expression Regulation, NeoplasticGenomicsMultiomicsPrognosis

Author keywords

cancermachine learningmulti-omicsprognosis

Substances

Biomarkers, Tumor

Authors and institutions

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 510060 Guangzhou, Guangdong, China.
  • Department of Molecular Pharmacology & Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
  • School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, 510006 Guangzhou, Guangdong, China.

Cite

APA

Xie, J., Xu, J., Tian, Z., Liang, J., & Tang, H. (2025). Extended Insights Into Advancing Multi-Omics and Prognostic Methods for Cancer Prognosis Forecasting. Frontiers in Bioscience-Landmark, 30(8). https://doi.org/10.31083/fbl44091

Vancouver

Xie J, Xu J, Tian Z, Liang J, Tang H. Extended Insights Into Advancing Multi-Omics and Prognostic Methods for Cancer Prognosis Forecasting. Frontiers in Bioscience-Landmark. 2025;30(8). doi:10.31083/fbl44091

BibTeX
@article{Xie2025,
  author = {Xie, Jindong and Xu, Junjie and Tian, Zhi and Liang, Jian and Tang, Hailin},
  title = {Extended Insights Into Advancing Multi-Omics and Prognostic Methods for Cancer Prognosis Forecasting},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  volume = {30},
  number = {8},
  doi = {10.31083/fbl44091}
}
Start for free →